NasdaqGM:AUPHBiotechs
Aurinia Data At EULAR 2026 And Insider Buys Shape LUPKYNIS Outlook
Aurinia Pharmaceuticals (NasdaqGM:AUPH) reported new AURORA 1 Phase 3 data at EULAR 2026 showing LUPKYNIS reduced the risk of renal events or death in lupus nephritis.
The findings were presented at a major international rheumatology congress, putting fresh clinical evidence for LUPKYNIS in front of global specialists.
Tang Capital Management increased its stake in Aurinia, and senior company executives acquired additional shares.
Aurinia focuses on therapies for autoimmune kidney disease,...